3:13 PM
 | 
Oct 06, 2017
 |  BioCentury  |  Finance

CRISPRing out new targets

Where investors think CRISPR drug discovery play KSQ can go with platform

Flagship Pioneering believes the CRISPRomics drug discovery technology of recently unveiled KSQ Therapeutics Inc. may have the potential to greatly reduce false positives in drug discovery.

On Oct. 2, KSQ emerged from stealth mode with a $76 million financing led by Flagship. Also participating were fellow founding investor Polaris Partners, Arch Venture Partners and Alexandria Equities. The financing includes a series A and B round that are not broken out.

CSO Frank Stegmeier told BioCentury the CRISPRomics platform uses the gene editing technology to...

Read the full 419 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >